Imagine a world where managing obesity could be as simple as a once-a-month injection. Sounds too good to be true, right? But Pfizer is turning this into a reality, and the results are nothing short of groundbreaking. In a recent mid-stage trial, Pfizer’s experimental obesity drug, acquired through Metsera, demonstrated impressive weight loss when administered just once a month. Here’s the kicker: patients lost up to 12.3% of their body weight by week 28, compared to those on a placebo. Even when accounting for all patients, regardless of whether they completed the trial, the weight loss was a notable 10.5%.
And this is the part most people miss: the drug, known as PF'3944, didn’t hit a plateau after patients switched to monthly dosing. This suggests that weight loss could continue as the study progresses to week 64. If proven true, this could be a game-changer for Pfizer, which is aiming to disrupt a market currently dominated by Eli Lilly and Novo Nordisk’s weekly injections. But here’s where it gets controversial: Pfizer’s injection is designed to be ultra-long-acting, meaning it stays active in the body longer than existing treatments like Novo’s Wegovy. Could this less frequent dosing schedule without sacrificing efficacy be the key to outperforming competitors?
Pfizer isn’t stopping here—they’re planning to launch 10 phase three trials for PF'3944 this year. Dr. Jim List, Pfizer’s chief internal medicine officer, stated, ‘These topline results reinforce the potential of PF'3944 as a monthly treatment with competitive efficacy.’ The announcement came on the same day Pfizer reported fourth-quarter earnings that exceeded expectations, adding to the buzz.
But here’s the real question: Can a monthly injection truly revolutionize obesity treatment, or is it too early to celebrate? The drug was well-tolerated, with mostly mild to moderate gastrointestinal side effects—typical for GLP-1 drugs. Only a small number of patients discontinued treatment due to side effects, and no new safety concerns were identified. Last year, Metsera reported even more striking results in a separate trial, with the highest dose leading to an average weight loss of 14.1% after 28 weekly doses.
Pfizer is also exploring PF'3944 as both a weekly and monthly injection, as well as in combination with other treatments targeting different gut hormones. In the trial, patients started with weekly injections before transitioning to monthly dosing, showcasing the drug’s flexibility. But here’s where it gets even more intriguing: If Pfizer succeeds, will this shift the entire obesity treatment landscape? And what does this mean for patients who struggle with daily or weekly regimens? Let us know your thoughts in the comments—is this the future of obesity treatment, or is there more to the story?
